2024
Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis
Mutonga M, Shewarega A, Gross M, Kahl V, Madoff D. Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis. Clinical Imaging 2024, 115: 110283. PMID: 39278042, DOI: 10.1016/j.clinimag.2024.110283.Peer-Reviewed Original ResearchBeta-blockersTumor responseImaging timepointsTumor sizeEtiology of liver diseaseAssociated with high mortalityTransplant free survivalTransplant-free survivalTreatment of hepatocellular carcinomaFavorable clinical outcomesChild-Pugh scoreFirst-line treatmentBeta-blocker groupPredictors of survivalCox regression analysisTreatment of HCCStudent's t-testFree survivalTransarterial chemoembolizationChi-square testPost-TACETACE treatmentPugh scoreSurvival predictorsAdjunctive useLBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
Llovet J, Finn R, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Li H, Kim J, Zhao H, Li C, Madoff D, Ghobrial R, El-Khoueiry A, Vogel A, Peng X, Mody K, Dubrovsky L, Kudo M. LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study. Annals Of Oncology 2024, 35: s1229. DOI: 10.1016/j.annonc.2024.08.2277.Peer-Reviewed Original ResearchTumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison.
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Ibrahim S, Fortune B, Talenfeld A, Madoff D, Johnson M, Sedrakyan A. Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison. American Journal Of Roentgenology 2024, 223: e2431272. PMID: 38899842, DOI: 10.2214/ajr.24.31272.Peer-Reviewed Original ResearchEarly-stage hepatocellular carcinomaHepatocellular carcinomaPost-procedure periodIndex procedureOut-of-pocket costsPatient out-of-pocket costsDrivers of high costsDays post-procedureSubgroup of patientsTreated with ablationPropensity-matched subgroupsU.S. population-based studyPopulation-based studySurgical resectionMultivariate linear regression modelSurgical treatmentPrognostic indicatorPost-procedureTreatment modalitiesTreatment optionsSEER-MedicareResectionMultivariate analysisTransplantationPropensity-scoreImage-guided percutaneous strategies to improve the resectability of HCC: Portal vein embolization, liver venous deprivation, or radiation lobectomy?
Chan S, Cornman-Homonoff J, Lucatelli P, Madoff D. Image-guided percutaneous strategies to improve the resectability of HCC: Portal vein embolization, liver venous deprivation, or radiation lobectomy? Clinical Imaging 2024, 111: 110185. PMID: 38781614, DOI: 10.1016/j.clinimag.2024.110185.Peer-Reviewed Original ResearchLiver venous deprivationPortal vein embolizationRadiation lobectomyVein embolizationResection of HCCMinimally invasive techniquesStandard of careHepatic malignanciesLiver remnantLiver insufficiencySurgical candidacySurgical techniqueHepatocellular carcinomaInvasive techniquesHepatic functionPercutaneous strategiesResectionPatient's likelihoodLobectomyEmbolizationLiverPatientsFLRCarcinomaMalignancyReply
Charalel R, Mushlin A, Mao J, Fortune B, Madoff D, Johnson M, Sedrakyan A. Reply. Journal Of The American College Of Radiology 2024, 21: 1331-1332. PMID: 38719105, DOI: 10.1016/j.jacr.2024.04.010.Peer-Reviewed Original ResearchAn Interventional Radiologist's Guide to Lung Cancer
Fish A, Madoff D. An Interventional Radiologist's Guide to Lung Cancer. Seminars In Interventional Radiology 2024, 41: 121-128. PMID: 38993601, PMCID: PMC11236454, DOI: 10.1055/s-0044-1786725.Peer-Reviewed Original ResearchLung cancer patientsLung cancerTissue diagnosisInterventional radiologistsCancer patientsField of interventional oncologyTreating lung cancer patientsTreatment of lung cancerEarly-stage diseaseAdvanced medical therapiesLung cancer complicationsBiopsy complicationsRadiation therapyPercutaneous ablationSurgical therapyMedical therapyInterventional oncologyEndovascular therapyInvasive treatmentCancer complicationsCancer deathTherapyGold standardCancerTreatment pathwaysEffect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma.
Shewarega A, Santana J, Nam D, Berz A, Tefera J, Kahl V, Mishra S, Coman D, Duncan J, Roberts S, Wetter A, Madoff D, Chapiro J. Effect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma. Radiology 2024, 310: e232365. PMID: 38349244, PMCID: PMC10902598, DOI: 10.1148/radiol.232365.Peer-Reviewed Original ResearchConceptsT cell infiltrationCD8<sup>+</sup> T cellsMatrix metalloproteinase inhibitionT cellsHepatocellular carcinomaMatrix metalloproteinase inhibitorsMatrix metalloproteinasesResidual tumorCXCR3<sup>+</sup> CD8<sup>+</sup> T cellsCytotoxic CD8<sup>+</sup> T cell infiltrationIntratumoral CD8+ T cell infiltrationCD8+ T cell infiltrationCD8<sup>+</sup> T cell infiltrationMouse model of hepatocellular carcinomaEarly-stage hepatocellular carcinomaImage-guided tumor ablationUnpaired Student's <i>t</i> testModel of hepatocellular carcinomaFirst-line therapyMurine hepatocellular carcinomaT cell subsetsTumor-associated macrophagesMurine HCC modelLocal immune responseFemale BALB/c miceAtezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
Stein S, Cheng W, Wiess C, Pollak J, Perez Lozada J, Chapiro J, Madoff D. Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC. Journal Of Clinical Oncology 2024, 42: tps584-tps584. DOI: 10.1200/jco.2024.42.3_suppl.tps584.Peer-Reviewed Original ResearchRates of grade 3Grade 3Child-Pugh A cirrhosisBCLC-B HCCCombination of atezolizumabCurative intent therapyMain portal veinRisk of bleedingDiagnosis of HCCSignificant autoimmune diseaseSingle arm pilot studyB HCCECOG PSEffective regimenOpen-labelOverall survivalGastroesophageal varicesIntent therapyPredicted probabilityAutoimmune diseasesHepatic arteryPortal veinHepatic encephalopathyPatientsImprove outcomes
2023
Predictors for Early Liver Cancer Survival After Ablation and Surgical Resection: A Surveillance, Epidemiology, and End Results Program-Medicare Study
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Fortune B, Talenfeld A, Madoff D, Ibrahim S, Johnson M, Sedrakyan A. Predictors for Early Liver Cancer Survival After Ablation and Surgical Resection: A Surveillance, Epidemiology, and End Results Program-Medicare Study. Journal Of The American College Of Radiology 2023, 21: 295-308. PMID: 37922972, DOI: 10.1016/j.jacr.2023.10.017.Peer-Reviewed Original ResearchCancer-specific mortalityCancer-specific deathSurgical resectionSocial determinantsPortal hypertensionTumor sizeTreatment characteristicsSmall HCCAsian raceDisease factorsMultivariable Cox regression modelsSEER-Medicare studyChronic kidney diseaseHigh-volume centersLarger tumor sizeCox regression modelSignificant protective factorCause mortalityClinical factorsEsophageal varicesIndependent predictorsSEER-MedicareKidney diseaseVolume centersProcedure yearHepatic Hypertrophy in Normal and Cirrhotic Livers Following Portal Vein Embolization: Comparative Assessment of 2 Different Embolic Regimens in a Large Animal Model
Kuhn T, Kahl V, Wang Y, Berz A, Shewarega A, Santana J, Antoch G, Chapiro J, Schlachter T, Madoff D. Hepatic Hypertrophy in Normal and Cirrhotic Livers Following Portal Vein Embolization: Comparative Assessment of 2 Different Embolic Regimens in a Large Animal Model. Journal Of Vascular And Interventional Radiology 2023, 34: 2162-2172.e2. PMID: 37634850, DOI: 10.1016/j.jvir.2023.08.024.Peer-Reviewed Original ResearchConceptsPortal vein embolizationFuture liver remnantVein embolizationLiver remnantCirrhotic liverStandardized future liver remnantNon-cirrhotic groupImmune cell infiltrationNon-cirrhotic liverN-butyl cyanoacrylateT-testFemale Yorkshire pigsLarge animal modelLarge animal studiesStudent's t-testCirrhotic groupEmbolized lobeBaseline percentageHepatic hypertrophyCell infiltrationBaseline CTKi-67Preclinical studiesInstitutional Animal CareFLR increaseBeyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Fortune B, Talenfeld A, Madoff D, Ibrahim S, Johnson M, Sedrakyan A. Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort. Journal Of Vascular And Interventional Radiology 2023, 34: 1997-2005.e3. PMID: 37468093, DOI: 10.1016/j.jvir.2023.07.010.Peer-Reviewed Original ResearchConceptsLiver transplantSurgical resectionHepatocellular carcinomaLT cohortBiliary injuryReadmission ratesAbscess formationIntensive care unit-level careLess healthcare utilizationNationally Representative CohortInitial hospital stayICU-level careAdverse event ratesEnd Results ProgramSmall hepatocellular carcinomaCare delivery outcomesFisher's exact testHealthcare Common Procedure Coding SystemChi-square testLow-intensity careLiver cancer treatmentPostprocedural hemorrhageHospital stayAdverse eventsSecondary outcomesBowel Injury during Percutaneous Radiologic Gastrostomy Tube Placement: A Case Series
Deshmukh A, Ali R, Madoff D, Silin D, Zuckerman D, Cornman-Homonoff J. Bowel Injury during Percutaneous Radiologic Gastrostomy Tube Placement: A Case Series. Journal Of Vascular And Interventional Radiology 2023, 34: 1462-1465. PMID: 37164038, DOI: 10.1016/j.jvir.2023.04.024.Peer-Reviewed Original ResearchEmerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments
Iezzi R, Gangi A, Posa A, Pua U, Liang P, Santos E, Kurup A, Tanzilli A, Tenore L, De Leoni D, Filippiadis D, Giuliante F, Valentini V, Gasbarrini A, Goldberg S, Meijerink M, Manfredi R, Kelekis A, Colosimo C, Madoff D. Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments. Cancers 2023, 15: 308. PMID: 36612304, PMCID: PMC9818393, DOI: 10.3390/cancers15010308.Peer-Reviewed Original ResearchInterventional oncologyLocoregional treatmentCancer patientsNew locoregional treatmentMultiple body systemsLow-risk alternativeImage-guided techniquesLocoregional proceduresSurgical therapyPalliative careInvasive proceduresPotential cureDisease sitesNew indicationsTreatment of diseasesInnovative indicationsOncologyPatientsTreatmentEvidence-reported literatureExpert discussionIndicationsWide spectrumReviewWidespread use
2022
Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver
Santana J, Shewarega A, Nam D, Kahl V, Madoff D, Zhang X, Chapiro J. Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver. Journal Of Vascular And Interventional Radiology 2022, 34: 404-408.e1. PMID: 36473611, PMCID: PMC11037556, DOI: 10.1016/j.jvir.2022.11.026.Peer-Reviewed Original ResearchConceptsLiver cirrhosisMale New Zealand white rabbitsRabbit liver tumor modelCirrhotic liver backgroundReproducible tumor growthVX2 liver cancerLeft hepatic lobeNew Zealand white rabbitsDuration of treatmentLiver tumor modelCross-sectional imagingVX2 rabbit liver tumor modelZealand white rabbitsHepatic lobeHistopathological evaluationMajor underlying factorHepatic tumorsIntragastric administrationHepatocellular carcinomaLiver tumorsLiver cancerCirrhosisUnmet needTumor growthVX2 tumorsMR Imaging–Based In Vivo Macrophage Imaging to Monitor Immune Response after Radiofrequency Ablation of the Liver
Santana J, Petukhova-Greenstein A, Gross M, Hyder F, Pekurovsky V, Gottwald L, Boustani A, Walsh J, Kucukkaya A, Malpani R, Madoff D, Goldberg S, Ahmed M, Joshi N, Coman D, Chapiro J. MR Imaging–Based In Vivo Macrophage Imaging to Monitor Immune Response after Radiofrequency Ablation of the Liver. Journal Of Vascular And Interventional Radiology 2022, 34: 395-403.e5. PMID: 36423815, PMCID: PMC11042914, DOI: 10.1016/j.jvir.2022.11.013.Peer-Reviewed Original ResearchConceptsImmune responseT1-weighted MRPrussian blue stainingRadiofrequency ablationRF ablationC57BL/6 wild-type miceMR imagingDose-escalation studyLocal immune responseMass cytometryWild-type miceRadiological-pathological correlationBlue stainingT1-weighted MR imagingHepatic radiofrequency ablationCD68 antibodyUntreated lobeVivo doseHepatic RF ablationVivo macrophagesMacrophagesMiceMR imaging scannerCoagulation areaCD68Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study
Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, Bilbao JI, Bouvier A, Chapiro J, Chiesa C, Decaens T, Denys A, Duran R, Edeline J, Garin E, Ghelfi J, Helmberger T, Irani F, Lam M, Lewandowski R, Liu D, Loffroy R, Madoff DC, Mastier C, Salem R, Sangro B, Sze D, Vilgrain V, Vouche M, Guiu B, Ronot M. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 50: 921-928. PMID: 36282299, DOI: 10.1007/s00259-022-06002-5.Peer-Reviewed Original ResearchConceptsSelective internal radiation therapyTextbook outcomeInternal radiation therapyHepatocellular carcinomaRadiation therapyPatient-important outcomesLarge observational studiesNuclear medicine physiciansEntire intervention processRandomized trialsRoutine careResultsA totalObservational studyMultistep interventionMedicine physiciansInterventional radiologistsSenior authorClinical roundsCarcinomaTherapyInterventionOutcomesLocoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?
Wang Y, Strazzabosco M, Madoff DC. Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice? Current Oncology Reports 2022, 24: 1741-1750. PMID: 36255606, PMCID: PMC10878124, DOI: 10.1007/s11912-022-01338-5.Peer-Reviewed Original ResearchConceptsLocoregional therapyIntrahepatic cholangiocarcinomaManagement of ICCFuture prospective randomized studiesComparable survival outcomesSafety of hepatectomyProspective Randomized StudyLocal tumor controlNon-surgical approachCurrent clinical practicePurpose of reviewUnresectable diseaseSurgical candidatesSystemic therapyVenous embolizationRandomized studyTransarterial embolizationDismal prognosisMultimodal treatmentSafety profileSurvival outcomesAblative therapyTumor controlPreoperative hypertrophyLiver lobeLong-Term Survival After Surgery Versus Ablation for Early Liver Cancer in a Large, Nationally Representative Cohort
Charalel RA, Mushlin AI, Li D, Mao J, Ibrahim S, Carlos R, Kwan SW, Fortune B, Talenfeld AD, Brown RS, Madoff DC, Johnson MS, Sedrakyan A. Long-Term Survival After Surgery Versus Ablation for Early Liver Cancer in a Large, Nationally Representative Cohort. Journal Of The American College Of Radiology 2022, 19: 1213-1223. PMID: 36208842, DOI: 10.1016/j.jacr.2022.07.010.Peer-Reviewed Original ResearchConceptsCancer-specific survivalSurgical resectionSmall hepatocellular carcinomaPrior treatment groupsHepatocellular carcinomaSurvival outcomesTreatment groupsSR groupPrior treatmentEnd Results Program-MedicarePropensity-matched hazard ratiosPropensity score-matched comparisonMedian study followNationally Representative CohortCancer-specific mortalityDisease-free survivalCox regression analysisKaplan-Meier curvesLog-rank testEarly liver cancerDifferential survival outcomesHealthcare Common Procedure Coding SystemCause mortalityCause survivalLiver transplantS2433 A Rare Case of Esophageal Perforation in Liposarcoma After Cryoablation
Samardzic T, Patel N, Ramras S, Detterbeck F, Madoff D. S2433 A Rare Case of Esophageal Perforation in Liposarcoma After Cryoablation. The American Journal Of Gastroenterology 2022, 117: e1624-e1625. DOI: 10.14309/01.ajg.0000866372.42343.f2.Peer-Reviewed Original Research